Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | See Remarks | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,765 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Sale · Disposed 587 · Balance 39,765 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 42,886 |
Reported balance
After 2026-09-25 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-25 · Exercise / conversion · Acquired 3,121 · Balance 42,886 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 39,765 |
Reported balance
After 2026-09-25 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-25 · Sale · Disposed 3,121 · Balance 39,765 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F2: Includes 39,575 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-03-31 | Direct | 93,625 |
Reported balance
After 2026-09-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-25 · Exercise / conversion · Disposed 3,121 · Balance 93,625 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F3: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
F2: Includes 39,575 restricted stock units.
F3: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2026 Filed Sep 28, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,121 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0002124509-26-000012 · ownership.xml · derivative · entry 4 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,625 Underlying: Common Stock · 3,121 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F3 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,121 | $200.54 | $625,885.34 |
DisclosureSEC source: 0002124509-26-000012 · ownership.xml · nonDerivative · entry 3 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,765 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F2 · balance_after: Includes 39,575 restricted stock units. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,121 | $33.62 | $104,928.02 |
DisclosureSEC source: 0002124509-26-000012 · ownership.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. Read SEC document |
| September 24, 2026 Filed Sep 28, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 587 | $200.00 | $117,400.00 |
DisclosureSEC source: 0002124509-26-000012 · ownership.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,765 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,764 | $196.94 | $347,402.16 |
DisclosureSEC source: 0002124509-26-000010 · ownership.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,352 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,747 | $199.30 | $348,182.69 |
DisclosureSEC source: 0002124509-26-000008 · ownership.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,116 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 39,575 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 27 | $195.05 | $5,266.41 |
DisclosureSEC source: 0002124509-26-000008 · ownership.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,863 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades at prices ranging from $195.03 to $195.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,363 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · derivative · entry 7 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,746 Underlying: Common Stock · 9,363 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F8 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $207.17 | $62,151.99 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 6 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,890 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F6 · price: The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7 · balance_after: Includes 43,700 restricted stock units. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,179 | $206.10 | $242,991.31 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 5 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,190 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F5 · price: The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,420 | $205.05 | $496,224.15 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 4 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,369 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F4 · price: The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,530 | $204.14 | $1,128,870.42 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 3 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,789 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F3 · price: The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 6,019 | $203.28 | $1,223,568.80 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,319 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F2 · price: The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 9,363 | $33.62 | $314,784.06 |
DisclosureSEC source: 0002124509-26-000004 · ownership.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,615 | $156.12 | $720,490.11 |
DisclosureSEC source: 0001610717-26-000247 · form4.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,975 F1 · kind: Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 43,700 Restricted Stock Units. F4 · balance_after: Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,121 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001610717-26-000166 · form4.xml · derivative · entry 5 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,109 Underlying: Common Stock · 3,121 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F6 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 421 | $154.82 | $65,177.41 |
DisclosureSEC source: 0001610717-26-000166 · form4.xml · nonDerivative · entry 4 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,400 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $154.70 to $154.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,000 | $154.06 | $308,121.80 |
DisclosureSEC source: 0001610717-26-000166 · form4.xml · nonDerivative · entry 3 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,821 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $153.65 to $154.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $153.30 | $107,311.61 |
DisclosureSEC source: 0001610717-26-000166 · form4.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,821 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $152.64 to $153.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,121 | $33.62 | $104,928.02 |
DisclosureSEC source: 0001610717-26-000166 · form4.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 21:50 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,120 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001610717-26-000158 · form4.xml · derivative · entry 5 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,230 Underlying: Common Stock · 3,120 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F6 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 21:50 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 400 | $134.34 | $53,734.00 |
DisclosureSEC source: 0001610717-26-000158 · form4.xml · nonDerivative · entry 4 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,400 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $134.04 to $134.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 21:50 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,049 | $132.88 | $139,387.76 |
DisclosureSEC source: 0001610717-26-000158 · form4.xml · nonDerivative · entry 3 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,800 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $132.37 to $133.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 21:50 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,671 | $131.66 | $220,007.03 |
DisclosureSEC source: 0001610717-26-000158 · form4.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,849 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $131.08 to $132.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 21:50 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,120 | $33.62 | $104,894.40 |
DisclosureSEC source: 0001610717-26-000158 · form4.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,450 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · derivative · entry 7 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,350 Underlying: Common Stock · 37,450 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F8 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 400 | $97.21 | $38,882.84 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 6 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,400 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $97.12 to $97.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 11,036 | $96.43 | $1,064,200.38 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 5 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,800 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $96.00 to $96.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 21,086 | $95.49 | $2,013,415.69 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 4 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,836 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $95.00 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,128 | $94.16 | $294,520.28 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 3 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,922 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $93.75 to $94.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,800 | $93.22 | $167,801.40 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 2 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,050 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $92.69 to $93.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 37,450 | $33.62 | $1,259,069.00 |
DisclosureSEC source: 0001610717-26-000137 · form4.xml · nonDerivative · entry 1 Mancini Anthony · CIK 0002124509 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. F2 · balance_after: Includes 54,400 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.